Canadian Hospital Specialties Limited acquires all product lines from Roxon Medi-Tech Ltd.

On February 16, 2021, Canadian Hospital Specialties Limited ("CHS") announced the acquisition of all product lines (excluding urology products) from Roxon Medi-Tech Ltd.  

CHS, a portfolio company of private equity firm Cortec Group, is a national specialty distributor of medical and surgical products focused on strategic partnerships to enhance the experience of its customers while focusing on improving patient outcomes.

The acquisition of Roxon will broaden CHS's footprint in the Cardiac Diagnostics and Monitoring and Neuro Monitoring spaces.  It also adds a Pulmonary testing portfolio to the existing Respiratory platform and augments the existing Pharmacy portfolio for both the acute and non-acute channel with the refrigeration portfolio.

Gowling WLG advised CHS in this acquisition with a team that included Ian Palm, David Torchetti and Aaron Goldstein.